Novartis (SWX:NOVN) is expanding its late stage pipeline through acquisitions, highlighted by the recent purchase of Avidity Biosciences. The Avidity deal brings three late stage genetic disorder ...

Avidity Biosciences, a Torrey Pines biopharmaceutical company, has closed its underwritten public offering of 12.13 million shares of common stock. That includes 1.58 million shares sold pursuant to ...

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity. Novartis is acquiring ...

The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per ...

Late-stage pipeline investment rises as acquisition adds three genetic disorder therapies and trims margins by up to 2%.

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other ...

Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity ...

LA JOLLA, Calif., Jan. 11, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody ...

H.C. Wainwright analysts led by Ananda Ghosh downgraded Avidity Biosciences to Neutral from Buy and set a $72 price forecast, matching the cash offer from Novartis AG. The analysts’ move follows ...

FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET "This World FSHD Day, we are excited to be joining ...

Six months after banking a $100 million venture round, Avidity Biosciences is heading to the public market. The company filed to raise up to $100 million in its IPO, which will push its lead muscle ...